The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion

Schlomann U, Wildeboer D, Webster A, Antropova O, Zeuschner D, Knight CG, Docherty AJP, Lambert M, Skelton L, Jockusch H, Bartsch JW (2002)
Journal of Biological Chemistry 277(50): 48210-48219.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ; ;
Abstract
ADAMs (a disintegrin and metalloprotease domains) are metalloprotease and disintegrin domain-containing transmembrane glycoproteins with proteolytic, cell adhesion, cell fusion, and cell signaling properties. ADAM8 was originally cloned from monocytic cells, and its distinct expression pattern indicates possible roles in both immunology and neuropathology. Here we describe our analysis of its biochemical properties. In transfected COS-7 cells, ADAM8 is localized to the plasma membrane and processed into two forms derived either by prodomain removal or as remnant protein comprising the extracellular region with the disintegrin domain at the N terminus. Proteolytic removal of the ADAM8 propeptide was completely blocked in mutant ADAM8 with a Glu(330) to Gln exchange (EQ-A8) in the Zn2+ binding motif (HE(330)LGHNLGMSHD), arguing for autocatalytic prodomain removal. In co-transfection experiments, the ectodomain but not the entire MP domain of ADAM8 was able to remove the prodomain from EQ-ADAM8. With cells expressing ADAM8, cell adhesion to a substrate-bound recombinant ADAM8 disintegrin/Cys-rich domain was observed in the absence of serum, blocked by an antibody directed against the ADAM8 disintegrin domain. Soluble ADAM8 protease, consisting of either the metalloprotease domain or the complete ectodomain, cleaved myelin basic protein and a fluorogenic peptide substrate, and was inhibited by batimastat (BB-94, IC50 similar to50 nM) but not by recombinant tissue inhibitor of matrix metalloproteinases 1, 2, 3, and 4. Our findings demonstrate that ADAM8 processing by autocatalysis leads to a potential sheddase and to a form of ADAM8 with a function in cell adhesion.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Schlomann U, Wildeboer D, Webster A, et al. The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion. Journal of Biological Chemistry. 2002;277(50):48210-48219.
Schlomann, U., Wildeboer, D., Webster, A., Antropova, O., Zeuschner, D., Knight, C. G., Docherty, A. J. P., et al. (2002). The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion. Journal of Biological Chemistry, 277(50), 48210-48219.
Schlomann, U., Wildeboer, D., Webster, A., Antropova, O., Zeuschner, D., Knight, C. G., Docherty, A. J. P., Lambert, M., Skelton, L., Jockusch, H., et al. (2002). The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion. Journal of Biological Chemistry 277, 48210-48219.
Schlomann, U., et al., 2002. The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion. Journal of Biological Chemistry, 277(50), p 48210-48219.
U. Schlomann, et al., “The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion”, Journal of Biological Chemistry, vol. 277, 2002, pp. 48210-48219.
Schlomann, U., Wildeboer, D., Webster, A., Antropova, O., Zeuschner, D., Knight, C.G., Docherty, A.J.P., Lambert, M., Skelton, L., Jockusch, H., Bartsch, J.W.: The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion. Journal of Biological Chemistry. 277, 48210-48219 (2002).
Schlomann, U, Wildeboer, D, Webster, A, Antropova, O, Zeuschner, D, Knight, CG, Docherty, AJP, Lambert, M, Skelton, L, Jockusch, Harald, and Bartsch, JW. “The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion”. Journal of Biological Chemistry 277.50 (2002): 48210-48219.
This data publication is cited in the following publications:
This publication cites the following data publications:

55 Citations in Europe PMC

Data provided by Europe PubMed Central.

ADAM8 as a drug target in pancreatic cancer.
Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Hofling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, Moss ML, Rasmussen FH, Miller MA, Lauffenburger DA, Tuveson DA, Nimsky C, Bartsch JW., Nat Commun 6(), 2015
PMID: 25629724
Sputum ADAM8 expression is increased in severe asthma and COPD.
Oreo KM, Gibson PG, Simpson JL, Wood LG, McDonald VM, Baines KJ., Clin. Exp. Allergy 44(3), 2014
PMID: 24147597
ADAM8 in asthma. Friend or foe to airway inflammation?
Chen J, Jiang X, Duan Y, Long J, Bartsch JW, Deng L., Am. J. Respir. Cell Mol. Biol. 49(6), 2013
PMID: 23837412
High expression of ADAM8 correlates with poor prognosis in hepatocellular carcinoma.
Zhang Y, Zha TZ, Hu BS, Jiang C, Ge ZJ, Zhang K, Tan YF., Surgeon 11(2), 2013
PMID: 22878099

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 12372841
PubMed | Europe PMC

Search this title in

Google Scholar